双甲衍生物作为11β-氧类固醇脱酶的强有力的抑制剂2:结构-活性研究
Xiya Ren1, Lei Shi2, Xinyue Chen3
1Department of Obstetrics and Gynecology, the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325027, China.
The Journal of steroid biochemistry and molecular biology
|December 19, 2025
概括
双甲衍生物 (BPADs) 是一种新的11β-基类固醇脱酶2型 (11β-HSD2) 的抑制剂. 4-基甲 (BPH) 是最强效的,对内分泌干扰有影响,特别是在怀孕期间.
科学领域:
- 内分泌学 在内分泌学.
- 生物化学 生化学
- 毒理学 毒理学 毒理学
背景情况:
- 由于内分泌干扰作用,双甲 (BPA) 的使用受到限制.
- 环替代衍生物 (BPAD) 越来越多地被用作BPA替代品.
- BPADs对11β-hydroxysteroid脱酶2型 (11β-HSD2) 的影响,对于葡萄糖皮质激素调节至关重要,基本上是未知的.
研究的目的:
- 研究BPADs对11β-HSD2.2的抑制作用.
- 阐明BPAD诱导的11β-HSD2抑制背后的机制.
- 评估BPADs潜在的内分泌干扰活性.
主要方法:
- 对六种BPAD进行11β-HSD2抑制活性查.
- 结构与活动关系 (SAR) 分析.
- 酶动力学,表面等离子体共振 (SPR) 和分子对接.
- 使用BeWo细胞进行细胞测试.
主要成果:
- 4-基甲 (BPH) 成为最强大的11β-HSD2抑制剂 (人体IC50=1.26μM).
- 水性和硬质散体被确定为通过SAR抑制BPAD的关键因素.
- BPADs表现出竞争性或混合类型的抑制,直接与11β-HSD2结合,特别是在残留物Asn167和Lys236.
- 由于特定的氨基酸替代 (Ser92→Thr92) 人类11β-HSD2对BPADs的敏感性高于老鼠的正因.
结论:
- BPADs,特别是BPH,是11β-HSD2的强有力的抑制剂,具有显著的内分泌干扰潜力.
- 该研究提供了对BPAD-11β-HSD2相互作用的机制性见解,确定了关键的结合部位和抑制类型.
- BPAD可以作为11β-HSD2研究的化学探针,并突出了由于胎盘11β-HSD2的保护作用而引起的产前暴露的担忧.
相关概念视频
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.8K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.8K
Structure-Activity Relationships and Drug Design
1.6K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.6K
Enzyme Inhibition
91.2K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
91.2K
Antihypertensive Drugs: Thiazide-Class Diuretics
1.5K
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
1.5K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
1.2K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.2K
Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems
654
Phase I biotransformation reactions are integral to drug metabolism, predominantly involving oxidative, reductive, and hydrolytic transformations. Chief among these are oxidative reactions, which enhance the hydrophilicity of xenobiotics and introduce polar functional groups to facilitate their elimination from the body.
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
654


